BSX · earnings call history
Boston Scientific Q1 FY26 — Solid 9.4% organic growth undercut by a rare full-year guidance cut on WATCHMAN, EP and Urology headwinds
Read the briefBoston Scientific Q4 FY25 — Strong Organic Growth and Differentiated Performance
Read the briefBoston Scientific Q3 FY25 — Strong Growth Across Portfolio, Raised Full-Year Outlook
Read the briefBoston Scientific Q4 FY24 — Strong Organic Growth and FARAPULSE Momentum
Read the briefBrowse all US companies on the earnings-call register.